See "Specific therapies in CLL: mechanisms of resistance and tactics for administration" on page 471. Duvelisib was the next PI3K inhibitor approved through the FDA, also depending on a section III randomized demo.a hundred thirty The efficacy and safety profile in the drug appear similar with All those of idelalisib, https://garrisonh318eow7.cosmicwiki.com/user